Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Celgene May Have Lost Positive Sentiment, But Its Growth Thesis Hasn’t Gone Anywhere

Courtesy of Benzinga.

Celgene May Have Lost Positive Sentiment, But Its Growth Thesis Hasn't Gone Anywhere

William Blair said in a note the double hit on Celgene Corporation (NASDAQ: CELG)’s Inflammation and Immunology franchise may have reversed positive sentiment, but the company’s growth thesis and pipeline optionality remains intact.

The firm reiterated its Outperform rating on the shares of the company, as it believes the sell-off in the shares in reaction to the results is overdone.

After declining 16.37 percent to $99.99 on Thursday in reaction to the company’s quarterly results, Celgene stock was seen trading down an incremental 0.44 percent at $99.55 in pre-market trading.

Analyst Andy Hsieh noted that the company reported third-quarter results, which revealed revenues of $3.29 billion, below the consensus estimate of $3.42 billion, with the shortfall attributable to weak U.S. Oetzla sales. However, Hsieh noted that adjusted earnings per share of $1.91 trumped estimates, helped by lower-than-expected operating expenses.

See also: Upside And Downside Scenarios For Celgene; Is The Selloff Overdone?

Giving its key takeaways, William Blair said, against the backdrop of mongersen’s clinical setback in Crohn’s disease, it is particularly disappointed with the Otezla miss. This miss, according to the firm, will intensify investor anxiety concerning the health of the company’s I&I franchise.

While noting that the magnitude of downward 2020 guidance revision is only moderate, the firm said the implied over-reliance on the hematology franchise left investors more worried.

Notwithstanding the downward spiral in the stock, the firm continues to estimate a 19.5 percent CAGR for earnings per share until 2020. Additionally, the firm said the management’s 2020 guidance may not fully reflect the potential of highly differentiated pipeline compounds, as the wave of new product cycles will begin to play out starting in 2019.

“In the near term, data set from the positive phase III SUNBEAM and RADIANCE studies could provide some reprieve to investor sentiment,” the firm said.

Latest Ratings for CELG

Date Firm Action From To
Oct 2017 Citigroup Maintains Neutral
Oct 2017 Cantor Fitzgerald Downgrades Overweight Neutral
Oct 2017 JMP Securities Downgrades Market Outperform Market Perform

View More Analyst Ratings for CELG


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings Long Ideas News Reiteration Analyst Ratings Trading Ideas Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!